 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase or decrease the[0m
[34mrisk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMPHOTERICIN B increase or decrease the[0m
[32mrisk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMPHOTERICIN B"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Concentration in Human Tissues<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> [0m
[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Organ<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Amphotericin [0m
[31mB<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tissue Concentration [0m[1;31m([0m[31m&#xB5;g/g[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Spleen<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" AMPHOTERICIN B: clinical_pharmacology_table: Rrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m290.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lung<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m222.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Liver<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m196.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lymph [0m
[31mNode<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Kidney<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6.9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Heart [0m
[1;31m0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m5[0m[31m.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Brain<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: indications_and_usage: INDICATIONS AND USAGE ABELCET Â® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of [0m
[31mconventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy [0m[1;31m([0m[31mSee DESCRIPTION OF[0m
[31mCLINICAL STUDIES[0m[1;31m)[0m[31m. DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from [0m[1;31m473[0m[31m patients were pooled from three open-label studies in which ABELCET Â® was provided for the treatment of patients with[0m
[31minvasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies [0m
[31mdemonstrated effectiveness of ABELCET Â® in the treatment of invasive fungal infections as a second line therapy. AMPHOTERICIN B: indications_and_usage: Patients were defined by their individual [0m
[31mphysician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of [0m[1;31m500[0m[31m mg of amphotericin B. Nephrotoxicity was[0m
[31mdefined as a serum creatinine that had increased to >[0m[1;31m2.5[0m[31m mg/dL in adults and >[0m[1;31m1.5[0m[31m mg/dL in pediatric patients, or a creatinine clearance of <[0m[1;31m25[0m[31m mL/min while receiving conventional amphotericin B [0m
[31mtherapy. Of the [0m[1;31m473[0m[31m patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was [0m[1;31m39[0m[31m years [0m[1;31m([0m[31mrange of <[0m[1;31m1[0m[31m to [0m[1;31m93[0m[31m years[0m[1;31m)[0m[31m; [0m[1;31m307[0m[31m patients were [0m
[31mmale and [0m[1;31m166[0m[31m female. Patients were Caucasian [0m[1;31m([0m[1;31m381[0m[31m, [0m[1;31m81[0m[31m%[0m[1;31m)[0m[31m, African-American [0m[1;31m([0m[1;31m41[0m[31m, [0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m, Hispanic [0m[1;31m([0m[1;31m27[0m[31m, [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m, Asian [0m[1;31m([0m[1;31m10[0m[31m, [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, and various other races [0m[1;31m([0m[1;31m14[0m[31m, [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m. AMPHOTERICIN B: indications_and_usage: The [0m
[31mmedian baseline neutrophil count was [0m[1;31m4[0m[31m,[0m[1;31m000[0m[31m PMN/mm3; of these, [0m[1;31m101[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m had a baseline neutrophil count <[0m[1;31m500[0m[31m/mm [0m[1;31m3[0m[31m . Two-hundred eighty-two patients of the [0m[1;31m473[0m[31m patients were considered evaluable for [0m
[31mresponse to therapy; the other [0m[1;31m191[0m[31m patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving [0m[1;31m4[0m[31m doses or less of ABELCET Â®[0m
[31m. For evaluable patients, the following fungal infections were treated [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m282[0m[1;31m)[0m[31m: aspergillosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m111[0m[1;31m)[0m[31m, candidiasis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m87[0m[1;31m)[0m[31m, zygomycosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m25[0m[1;31m)[0m[31m, cryptococcosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m16[0m[1;31m)[0m[31m, and fusariosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m11[0m[1;31m)[0m[31m. There were [0m
[31mfewer than [0m[1;31m10[0m[31m evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. AMPHOTERICIN B: [0m
[31mindications_and_usage: However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative [0m
[31mantifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET Â® when serum creatinine was above [0m[1;31m2.5[0m[31m mg/dL experienced a decline in serum creatinine during [0m
[31mtreatment [0m[1;31m([0m[31mFigure [0m[1;31m1[0m[1;31m)[0m[31m. Serum creatinine levels were also lower during treatment with ABELCET Â® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a [0m
[31mretrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of[0m
[31mpatients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of patients at each time point.      [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: adverse_reactions_table: <table [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"42[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"58[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Events <sup>a<[0m[31m/[0m[31msup[0m[31m>with an Incidence of &#x2265;[0m[1;31m3[0m[31m% [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m556[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Event<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Percentage [0m[1;31m([0m[31m%[0m[1;31m)[0m
[31mof Patients<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Chills<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m18[0m[31m AMPHOTERICIN B: [0m
[31madverse_reactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Fever<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m14[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Increased Serum Creatinine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Multiple Organ Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Nausea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td AMPHOTERICIN B: adverse_reactions_table: [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypotension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Respiratory Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Vomiting<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Dyspnea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m" AMPHOTERICIN B: adverse_reactions_table: top"[0m[31m><paragraph>Sepsis<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Diarrhea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Headache<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cardiac Arrest<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypertension<[0m[31m/[0m[31mparagraph[0m[1;31m>[0m[31m<[0m[31m/[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET Â® does not distinguish [0m
[31mamphotericin B that is complexed with the phospholipids of ABELCET Â® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET Â® are [0m
[31mnonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET Â® , resulting in less than proportional increases in blood concentrations of amphotericin B over a [0m
[31mdose range of [0m[1;31m0.6[0m[31m-[0m[1;31m5[0m[31m mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET Â® and amphotericin B desoxycholate are: [0m
[31mPharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET Â® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET Â® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m5[0m[31m-[0m[1;31m7[0m
[31mdays Mean Â± SD Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day for [0m[1;31m42[0m[31m days a Mean Â± SD Peak Concentration [0m[1;31m([0m[31m Î¼g/mL[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Â± [0m[1;31m0.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[1;31m)[0m[31m b [0m[1;31m1.1[0m[31m Â± [0m[1;31m0.2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Concentration at End of Dosing Interval [0m[1;31m([0m[31mÎ¼g/mL[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Â± [0m[1;31m0.3[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[31m b [0m[1;31m0.4[0m
[31mÂ± [0m[1;31m0[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Area Under Blood Concentration-Time Curve [0m[1;31m([0m[31mAUC [0m[1;31m0[0m[31m-24h [0m[1;31m)[0m[31m [0m[1;31m([0m[31mÎ¼g*h/mL[0m[1;31m)[0m[31m [0m[1;31m14.0[0m[31m Â± [0m[1;31m7.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m[1;31m17.1[0m[31m Â± [0m[1;31m5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Clearance [0m[1;31m([0m[31mmL/h*kg[0m[1;31m)[0m[31m [0m[1;31m436.0[0m[31m.Â± [0m[1;31m188.5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m
[1;31m38.0[0m[31m Â± [0m[1;31m15[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Apparent Volume of Distribution [0m[1;31m([0m[31mVd area [0m[1;31m)[0m[31m [0m[1;31m([0m[31mL/kg[0m[1;31m)[0m[31m [0m[1;31m131.0[0m[31m.Â± [0m[1;31m57.7[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m5.0[0m[31m.Â± [0m[1;31m2.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Terminal Elimination Half-Life [0m[1;31m([0m[31mh[0m[1;31m)[0m[31m [0m[1;31m173.4[0m[31m Â± [0m[1;31m78.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m91.1[0m[31m Â± [0m[1;31m40.9[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Amount Excreted in [0m
[31mUrine Over [0m[1;31m24[0m[31m h After Last Dose [0m[1;31m([0m[31m% of dose[0m[1;31m)[0m[31m d [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased [0m
[31mapproximately [0m[1;31m34[0m[31m% from day [0m[1;31m1[0m[31m after the administration of ABELCET Â® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m7[0m[31m days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET Â® has not been studied. Tissue [0m
[31mconcentrations of amphotericin B have been obtained at autopsy from one heart transplant patient who received three doses of ABELCET Â® at [0m[1;31m5.3[0m[31m mg/kg/day: Concentration in Human Tissues Organ [0m
[31mAmphotericin B Tissue Concentration [0m[1;31m([0m[31mÂµg/g[0m[1;31m)[0m[31m Spleen [0m[1;31m290.0[0m[31m Lung [0m[1;31m222.0[0m[31m Liver [0m[1;31m196.0[0m[31m Lymph Node [0m[1;31m7.6[0m[31m Kidney [0m[1;31m6.9[0m[31m Heart [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m. Brain [0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m6[0m[31m This pattern of distribution is [0m
[31mconsistent with that observed in preclinical studies in dogs in which greatest concentrations of amphotericin B after ABELCET Â® administration were observed in the liver, spleen, and lung; however, [0m
[31mthe relationship of tissue concentrations of amphotericin B to its biological activity when administered as ABELCET Â® is unknown. Special Populations Hepatic Impairment: The effect of hepatic [0m
[31mimpairment on the disposition of ABELCET Â® is not known. Renal Impairment: The effect of renal impairment on the disposition of ABELCET Â® is not known. The effect of dialysis on the elimination of [0m
[31mABELCET Â® has not been studied; however, amphotericin B is not removed by hemodialysis when administered as amphotericin B desoxycholate. AMPHOTERICIN B: clinical_pharmacology: Pediatric and Elderly [0m
[31mPatients: The pharmacokinetics and pharmacodynamics of pediatric patients [0m[1;31m([0m[31mâ‰¤[0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m and elderly patients [0m[1;31m([0m[31mâ‰¥[0m[1;31m65[0m[31m years of age[0m[1;31m)[0m[31m have not been studied.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMPHOTERICIN B"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does AMPHOTERICIN B increase or decrease the risk of[0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMPHOTERICIN B increase or decrease the[0m
[32mrisk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMPHOTERICIN B"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Concentration in Human Tissues<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> [0m
[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Organ<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Amphotericin [0m
[31mB<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tissue Concentration [0m[1;31m([0m[31m&#xB5;g/g[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Spleen<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" AMPHOTERICIN B: clinical_pharmacology_table: Rrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m290.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lung<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m222.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Liver<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m196.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lymph [0m
[31mNode<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Kidney<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6.9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Heart [0m
[1;31m0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m5[0m[31m.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Brain<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: indications_and_usage: INDICATIONS AND USAGE ABELCET Â® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of [0m
[31mconventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy [0m[1;31m([0m[31mSee DESCRIPTION OF[0m
[31mCLINICAL STUDIES[0m[1;31m)[0m[31m. DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from [0m[1;31m473[0m[31m patients were pooled from three open-label studies in which ABELCET Â® was provided for the treatment of patients with[0m
[31minvasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies [0m
[31mdemonstrated effectiveness of ABELCET Â® in the treatment of invasive fungal infections as a second line therapy. AMPHOTERICIN B: indications_and_usage: Patients were defined by their individual [0m
[31mphysician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of [0m[1;31m500[0m[31m mg of amphotericin B. Nephrotoxicity was[0m
[31mdefined as a serum creatinine that had increased to >[0m[1;31m2.5[0m[31m mg/dL in adults and >[0m[1;31m1.5[0m[31m mg/dL in pediatric patients, or a creatinine clearance of <[0m[1;31m25[0m[31m mL/min while receiving conventional amphotericin B [0m
[31mtherapy. Of the [0m[1;31m473[0m[31m patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was [0m[1;31m39[0m[31m years [0m[1;31m([0m[31mrange of <[0m[1;31m1[0m[31m to [0m[1;31m93[0m[31m years[0m[1;31m)[0m[31m; [0m[1;31m307[0m[31m patients were [0m
[31mmale and [0m[1;31m166[0m[31m female. Patients were Caucasian [0m[1;31m([0m[1;31m381[0m[31m, [0m[1;31m81[0m[31m%[0m[1;31m)[0m[31m, African-American [0m[1;31m([0m[1;31m41[0m[31m, [0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m, Hispanic [0m[1;31m([0m[1;31m27[0m[31m, [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m, Asian [0m[1;31m([0m[1;31m10[0m[31m, [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, and various other races [0m[1;31m([0m[1;31m14[0m[31m, [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m. AMPHOTERICIN B: indications_and_usage: The [0m
[31mmedian baseline neutrophil count was [0m[1;31m4[0m[31m,[0m[1;31m000[0m[31m PMN/mm3; of these, [0m[1;31m101[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m had a baseline neutrophil count <[0m[1;31m500[0m[31m/mm [0m[1;31m3[0m[31m . Two-hundred eighty-two patients of the [0m[1;31m473[0m[31m patients were considered evaluable for [0m
[31mresponse to therapy; the other [0m[1;31m191[0m[31m patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving [0m[1;31m4[0m[31m doses or less of ABELCET Â®[0m
[31m. For evaluable patients, the following fungal infections were treated [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m282[0m[1;31m)[0m[31m: aspergillosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m111[0m[1;31m)[0m[31m, candidiasis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m87[0m[1;31m)[0m[31m, zygomycosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m25[0m[1;31m)[0m[31m, cryptococcosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m16[0m[1;31m)[0m[31m, and fusariosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m11[0m[1;31m)[0m[31m. There were [0m
[31mfewer than [0m[1;31m10[0m[31m evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. AMPHOTERICIN B: [0m
[31mindications_and_usage: However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative [0m
[31mantifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET Â® when serum creatinine was above [0m[1;31m2.5[0m[31m mg/dL experienced a decline in serum creatinine during [0m
[31mtreatment [0m[1;31m([0m[31mFigure [0m[1;31m1[0m[1;31m)[0m[31m. Serum creatinine levels were also lower during treatment with ABELCET Â® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a [0m
[31mretrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of[0m
[31mpatients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of patients at each time point.      [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: adverse_reactions_table: <table [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"42[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"58[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Events <sup>a<[0m[31m/[0m[31msup[0m[31m>with an Incidence of &#x2265;[0m[1;31m3[0m[31m% [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m556[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Event<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Percentage [0m[1;31m([0m[31m%[0m[1;31m)[0m
[31mof Patients<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Chills<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m18[0m[31m AMPHOTERICIN B: [0m
[31madverse_reactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Fever<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m14[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Increased Serum Creatinine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Multiple Organ Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Nausea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td AMPHOTERICIN B: adverse_reactions_table: [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypotension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Respiratory Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Vomiting<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Dyspnea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m" AMPHOTERICIN B: adverse_reactions_table: top"[0m[31m><paragraph>Sepsis<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Diarrhea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Headache<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cardiac Arrest<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypertension<[0m[31m/[0m[31mparagraph[0m[1;31m>[0m[31m<[0m[31m/[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET Â® does not distinguish [0m
[31mamphotericin B that is complexed with the phospholipids of ABELCET Â® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET Â® are [0m
[31mnonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET Â® , resulting in less than proportional increases in blood concentrations of amphotericin B over a [0m
[31mdose range of [0m[1;31m0.6[0m[31m-[0m[1;31m5[0m[31m mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET Â® and amphotericin B desoxycholate are: [0m
[31mPharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET Â® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET Â® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m5[0m[31m-[0m[1;31m7[0m
[31mdays Mean Â± SD Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day for [0m[1;31m42[0m[31m days a Mean Â± SD Peak Concentration [0m[1;31m([0m[31m Î¼g/mL[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Â± [0m[1;31m0.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[1;31m)[0m[31m b [0m[1;31m1.1[0m[31m Â± [0m[1;31m0.2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Concentration at End of Dosing Interval [0m[1;31m([0m[31mÎ¼g/mL[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Â± [0m[1;31m0.3[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[31m b [0m[1;31m0.4[0m
[31mÂ± [0m[1;31m0[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Area Under Blood Concentration-Time Curve [0m[1;31m([0m[31mAUC [0m[1;31m0[0m[31m-24h [0m[1;31m)[0m[31m [0m[1;31m([0m[31mÎ¼g*h/mL[0m[1;31m)[0m[31m [0m[1;31m14.0[0m[31m Â± [0m[1;31m7.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m[1;31m17.1[0m[31m Â± [0m[1;31m5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Clearance [0m[1;31m([0m[31mmL/h*kg[0m[1;31m)[0m[31m [0m[1;31m436.0[0m[31m.Â± [0m[1;31m188.5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m
[1;31m38.0[0m[31m Â± [0m[1;31m15[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Apparent Volume of Distribution [0m[1;31m([0m[31mVd area [0m[1;31m)[0m[31m [0m[1;31m([0m[31mL/kg[0m[1;31m)[0m[31m [0m[1;31m131.0[0m[31m.Â± [0m[1;31m57.7[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m5.0[0m[31m.Â± [0m[1;31m2.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Terminal Elimination Half-Life [0m[1;31m([0m[31mh[0m[1;31m)[0m[31m [0m[1;31m173.4[0m[31m Â± [0m[1;31m78.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m91.1[0m[31m Â± [0m[1;31m40.9[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Amount Excreted in [0m
[31mUrine Over [0m[1;31m24[0m[31m h After Last Dose [0m[1;31m([0m[31m% of dose[0m[1;31m)[0m[31m d [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased [0m
[31mapproximately [0m[1;31m34[0m[31m% from day [0m[1;31m1[0m[31m after the administration of ABELCET Â® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m7[0m[31m days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET Â® has not been studied. Tissue [0m
[31mconcentrations of amphotericin B have been obtained at autopsy from one heart transplant patient who received three doses of ABELCET Â® at [0m[1;31m5.3[0m[31m mg/kg/day: Concentration in Human Tissues Organ [0m
[31mAmphotericin B Tissue Concentration [0m[1;31m([0m[31mÂµg/g[0m[1;31m)[0m[31m Spleen [0m[1;31m290.0[0m[31m Lung [0m[1;31m222.0[0m[31m Liver [0m[1;31m196.0[0m[31m Lymph Node [0m[1;31m7.6[0m[31m Kidney [0m[1;31m6.9[0m[31m Heart [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m. Brain [0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m6[0m[31m This pattern of distribution is [0m
[31mconsistent with that observed in preclinical studies in dogs in which greatest concentrations of amphotericin B after ABELCET Â® administration were observed in the liver, spleen, and lung; however, [0m
[31mthe relationship of tissue concentrations of amphotericin B to its biological activity when administered as ABELCET Â® is unknown. Special Populations Hepatic Impairment: The effect of hepatic [0m
[31mimpairment on the disposition of ABELCET Â® is not known. Renal Impairment: The effect of renal impairment on the disposition of ABELCET Â® is not known. The effect of dialysis on the elimination of [0m
[31mABELCET Â® has not been studied; however, amphotericin B is not removed by hemodialysis when administered as amphotericin B desoxycholate. AMPHOTERICIN B: clinical_pharmacology: Pediatric and Elderly [0m
[31mPatients: The pharmacokinetics and pharmacodynamics of pediatric patients [0m[1;31m([0m[31mâ‰¤[0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m and elderly patients [0m[1;31m([0m[31mâ‰¥[0m[1;31m65[0m[31m years of age[0m[1;31m)[0m[31m have not been studied.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMPHOTERICIN B increase or decrease the[0m
[32mrisk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMPHOTERICIN B"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does AMPHOTERICIN B increase or decrease the risk of[0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMPHOTERICIN B increase or decrease the[0m
[32mrisk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMPHOTERICIN B increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMPHOTERICIN B"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"50[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Concentration in Human Tissues<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph> [0m
[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Organ<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Amphotericin [0m
[31mB<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tissue Concentration [0m[1;31m([0m[31m&#xB5;g/g[0m[1;31m)[0m[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Spleen<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" AMPHOTERICIN B: clinical_pharmacology_table: Rrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m290.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m
[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lung<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m222.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Liver<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m196.0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Lymph [0m
[31mNode<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Kidney<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6.9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Heart [0m
[1;31m0[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m5[0m[31m.<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Botrule[0m[31m Lrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Brain<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology_table: [0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: indications_and_usage: INDICATIONS AND USAGE ABELCET Â® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of [0m
[31mconventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy [0m[1;31m([0m[31mSee DESCRIPTION OF[0m
[31mCLINICAL STUDIES[0m[1;31m)[0m[31m. DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from [0m[1;31m473[0m[31m patients were pooled from three open-label studies in which ABELCET Â® was provided for the treatment of patients with[0m
[31minvasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies [0m
[31mdemonstrated effectiveness of ABELCET Â® in the treatment of invasive fungal infections as a second line therapy. AMPHOTERICIN B: indications_and_usage: Patients were defined by their individual [0m
[31mphysician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of [0m[1;31m500[0m[31m mg of amphotericin B. Nephrotoxicity was[0m
[31mdefined as a serum creatinine that had increased to >[0m[1;31m2.5[0m[31m mg/dL in adults and >[0m[1;31m1.5[0m[31m mg/dL in pediatric patients, or a creatinine clearance of <[0m[1;31m25[0m[31m mL/min while receiving conventional amphotericin B [0m
[31mtherapy. Of the [0m[1;31m473[0m[31m patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was [0m[1;31m39[0m[31m years [0m[1;31m([0m[31mrange of <[0m[1;31m1[0m[31m to [0m[1;31m93[0m[31m years[0m[1;31m)[0m[31m; [0m[1;31m307[0m[31m patients were [0m
[31mmale and [0m[1;31m166[0m[31m female. Patients were Caucasian [0m[1;31m([0m[1;31m381[0m[31m, [0m[1;31m81[0m[31m%[0m[1;31m)[0m[31m, African-American [0m[1;31m([0m[1;31m41[0m[31m, [0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m, Hispanic [0m[1;31m([0m[1;31m27[0m[31m, [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m, Asian [0m[1;31m([0m[1;31m10[0m[31m, [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, and various other races [0m[1;31m([0m[1;31m14[0m[31m, [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m. AMPHOTERICIN B: indications_and_usage: The [0m
[31mmedian baseline neutrophil count was [0m[1;31m4[0m[31m,[0m[1;31m000[0m[31m PMN/mm3; of these, [0m[1;31m101[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m had a baseline neutrophil count <[0m[1;31m500[0m[31m/mm [0m[1;31m3[0m[31m . Two-hundred eighty-two patients of the [0m[1;31m473[0m[31m patients were considered evaluable for [0m
[31mresponse to therapy; the other [0m[1;31m191[0m[31m patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving [0m[1;31m4[0m[31m doses or less of ABELCET Â®[0m
[31m. For evaluable patients, the following fungal infections were treated [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m282[0m[1;31m)[0m[31m: aspergillosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m111[0m[1;31m)[0m[31m, candidiasis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m87[0m[1;31m)[0m[31m, zygomycosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m25[0m[1;31m)[0m[31m, cryptococcosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m16[0m[1;31m)[0m[31m, and fusariosis [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m11[0m[1;31m)[0m[31m. There were [0m
[31mfewer than [0m[1;31m10[0m[31m evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. AMPHOTERICIN B: [0m
[31mindications_and_usage: However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative [0m
[31mantifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET Â® when serum creatinine was above [0m[1;31m2.5[0m[31m mg/dL experienced a decline in serum creatinine during [0m
[31mtreatment [0m[1;31m([0m[31mFigure [0m[1;31m1[0m[1;31m)[0m[31m. Serum creatinine levels were also lower during treatment with ABELCET Â® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a [0m
[31mretrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of[0m
[31mpatients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [0m[1;31m[[0m[31m [0m[1;31m][0m[31m= Number of patients at each time point.      [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: adverse_reactions_table: <table [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"42[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"58[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Events <sup>a<[0m[31m/[0m[31msup[0m[31m>with an Incidence of &#x2265;[0m[1;31m3[0m[31m% [0m[1;31m([0m[31mN[0m[31m=[0m[1;31m556[0m[1;31m)[0m[31m <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Adverse Event<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Percentage [0m[1;31m([0m[31m%[0m[1;31m)[0m
[31mof Patients<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Chills<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m18[0m[31m AMPHOTERICIN B: [0m
[31madverse_reactions_table: <[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Fever<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m14[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Increased Serum Creatinine<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Multiple Organ Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m11[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Nausea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m9[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td AMPHOTERICIN B: adverse_reactions_table: [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypotension<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Respiratory Failure<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Vomiting<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m8[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Dyspnea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m" AMPHOTERICIN B: adverse_reactions_table: top"[0m[31m><paragraph>Sepsis<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m7[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Diarrhea<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Headache<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Cardiac Arrest<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>[0m[1;31m6[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Hypertension<[0m[31m/[0m[31mparagraph[0m[1;31m>[0m[31m<[0m[31m/[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: openfda: pharm_class_cs         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the blood after the administration of ABELCET Â® does not distinguish [0m
[31mamphotericin B that is complexed with the phospholipids of ABELCET Â® from amphotericin B that is uncomplexed. The pharmacokinetics of amphotericin B after the administration of ABELCET Â® are [0m
[31mnonlinear. Volume of distribution and clearance from blood increase with increasing dose of ABELCET Â® , resulting in less than proportional increases in blood concentrations of amphotericin B over a [0m
[31mdose range of [0m[1;31m0.6[0m[31m-[0m[1;31m5[0m[31m mg/kg/day. AMPHOTERICIN B: clinical_pharmacology: The pharmacokinetics of amphotericin B in whole blood after the administration of ABELCET Â® and amphotericin B desoxycholate are: [0m
[31mPharmacokinetic Parameters of Amphotericin B in Whole Blood in Patients Administered Multiple Doses of ABELCET Â® or Amphotericin B Desoxycholate Pharmacokinetic Parameter ABELCET Â® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m5[0m[31m-[0m[1;31m7[0m
[31mdays Mean Â± SD Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day for [0m[1;31m42[0m[31m days a Mean Â± SD Peak Concentration [0m[1;31m([0m[31m Î¼g/mL[0m[1;31m)[0m[31m [0m[1;31m1.7[0m[31m Â± [0m[1;31m0.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[1;31m)[0m[31m b [0m[1;31m1.1[0m[31m Â± [0m[1;31m0.2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Concentration at End of Dosing Interval [0m[1;31m([0m[31mÎ¼g/mL[0m[1;31m)[0m[31m [0m[1;31m0.6[0m[31m Â± [0m[1;31m0.3[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m10[0m[31m b [0m[1;31m0.4[0m
[31mÂ± [0m[1;31m0[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m2[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Area Under Blood Concentration-Time Curve [0m[1;31m([0m[31mAUC [0m[1;31m0[0m[31m-24h [0m[1;31m)[0m[31m [0m[1;31m([0m[31mÎ¼g*h/mL[0m[1;31m)[0m[31m [0m[1;31m14.0[0m[31m Â± [0m[1;31m7.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m[1;31m17.1[0m[31m Â± [0m[1;31m5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Clearance [0m[1;31m([0m[31mmL/h*kg[0m[1;31m)[0m[31m [0m[1;31m436.0[0m[31m.Â± [0m[1;31m188.5[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m14[0m[1;31m)[0m[31m b,c [0m
[1;31m38.0[0m[31m Â± [0m[1;31m15[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Apparent Volume of Distribution [0m[1;31m([0m[31mVd area [0m[1;31m)[0m[31m [0m[1;31m([0m[31mL/kg[0m[1;31m)[0m[31m [0m[1;31m131.0[0m[31m.Â± [0m[1;31m57.7[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m5.0[0m[31m.Â± [0m[1;31m2.8[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Terminal Elimination Half-Life [0m[1;31m([0m[31mh[0m[1;31m)[0m[31m [0m[1;31m173.4[0m[31m Â± [0m[1;31m78.0[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m8[0m[1;31m)[0m[31m c [0m[1;31m91.1[0m[31m Â± [0m[1;31m40.9[0m[31m [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m5[0m[1;31m)[0m[31m Amount Excreted in [0m
[31mUrine Over [0m[1;31m24[0m[31m h After Last Dose [0m[1;31m([0m[31m% of dose[0m[1;31m)[0m[31m d [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m


[31mCONTENT: AMPHOTERICIN B: clinical_pharmacology: Although amphotericin B is excreted slowly, there is little accumulation in the blood after repeated dosing. AUC of amphotericin B increased [0m
[31mapproximately [0m[1;31m34[0m[31m% from day [0m[1;31m1[0m[31m after the administration of ABELCET Â® [0m[1;31m5[0m[31m mg/kg/day for [0m[1;31m7[0m[31m days. The effect of gender or ethnicity on the pharmacokinetics of ABELCET Â® has not been studied. Tissue [0m
[31mconcentrations of amphotericin B have been obtained at autopsy from one heart transplant patient who received three doses of ABELCET Â® at [0m[1;31m5.3[0m[31m mg/kg/day: Concentration in Human Tissues Organ [0m
[31mAmphotericin B Tissue Concentration [0m[1;31m([0m[31mÂµg/g[0m[1;31m)[0m[31m Spleen [0m[1;31m290.0[0m[31m Lung [0m[1;31m222.0[0m[31m Liver [0m[1;31m196.0[0m[31m Lymph Node [0m[1;31m7.6[0m[31m Kidney [0m[1;31m6.9[0m[31m Heart [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m. Brain [0m[1;31m1[0m[31m. AMPHOTERICIN B: clinical_pharmacology: [0m[1;31m6[0m[31m This pattern of distribution is [0m
[31mconsistent with that observed in preclinical studies in dogs in which greatest concentrations of amphotericin B after ABELCET Â® administration were observed in the liver, spleen, and lung; however, [0m
[31mthe relationship of tissue concentrations of amphotericin B to its biological activity when administered as ABELCET Â® is unknown. Special Populations Hepatic Impairment: The effect of hepatic [0m
[31mimpairment on the disposition of ABELCET Â® is not known. Renal Impairment: The effect of renal impairment on the disposition of ABELCET Â® is not known. The effect of dialysis on the elimination of [0m
[31mABELCET Â® has not been studied; however, amphotericin B is not removed by hemodialysis when administered as amphotericin B desoxycholate. AMPHOTERICIN B: clinical_pharmacology: Pediatric and Elderly [0m
[31mPatients: The pharmacokinetics and pharmacodynamics of pediatric patients [0m[1;31m([0m[31mâ‰¤[0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m and elderly patients [0m[1;31m([0m[31mâ‰¥[0m[1;31m65[0m[31m years of age[0m[1;31m)[0m[31m have not been studied.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMPHOTERICIN B label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMPHOTERICIN B[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label data does not specify whether Amphotericin B increases or decreases the risk of mortality after myocardial infarction. Therefore, I cannot provide a reliable answer to this question [0m
[32mbased on the available data.[0m
